SVF
Level D· Preclinical EvidenceAnimal Study

Platelet lysate derived macroporous hydrogel loaded with adipose stem cells for spinal cord injury repair.

Wang YF., Huang YQ., Cao HT., Wang Y., Wang JL., Deng JJ.

Animal Study on Spinal Cord Injury, Scar, Chronic Inflammation, published in Biomater Adv (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biomater Adv (2026)
Country
Netherlands
Reported sample size
—
PMID
41875610
DOI
10.1016/j.bioadv.2026.214815

Abstract (original English)

Spinal cord injury (SCI) can result in irreversible neurological deficits, such as limb paralysis and dysfunctions of urination and defecation. Currently, there remains a dearth of effective therapeutic strategies to fully reverse the detrimental consequences of SCI. Stem cell transplantation, particularly adipose-derived stem cells (ASCs) transplantation, shows great promise in treating SCI. However, the low survival rate of transplanted cells and limited neural differentiation impede its long-term clinical effectiveness. In this study, platelet lysate-rich plasma (PLP) was utilized as the primary matrix component. Through sodium alginate cross-linking, a platelet lysate-rich plasma hydrogel (PLPH) with a micron-scale macroporous structure was fabricated. By precisely modulating the component ratios, PLPH was engineered to possess a low Young's modulus (approximately 1000 Pa), which is comparable to that of spinal cord tissue, along with characteristics such as a low swelling ratio, high porosity, and slow degradation. In vitro, PLPH facilitated the proliferation of ASCs and offered neuroprotection under oxidative stress conditions. Moreover, it promoted axonal growth in neuronal cells. In a mouse model of spinal cord injury, PLPH-loaded ASCs induced M2 polarization of microglia/macrophages at the injury site by activating the signal transducer and activator of transcription 6

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
Spinal Cord InjuriesAnimalsAdipose TissueHydrogelsMiceStem CellsPorosityBlood PlateletsStem Cell TransplantationFemale
Back & SpineSpinal Cord InjuryScarChronic Inflammation
View on PubMedDOI

Related research